BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
Get Our Industry eNewsletter FREE email:    
   

PPD, Inc. (PPDI) Makes Equity Investment In Accentia, Inc.


10/19/2005 5:09:55 PM

WILMINGTON, N.C., and TAMPA, Fla., Feb. 2 /PRNewswire-FirstCall/ -- PPD, Inc. and Accentia, Inc. today announced PPD has made a $5 million equity investment in Accentia. Under the terms of the agreements, PPD purchased shares of Accentia's Series E convertible preferred stock. In addition to the customary terms associated with investments of this nature, Accentia's Series E shares will pay a dividend based on a percentage of net sales of certain Accentia products.

Accentia is in the business of commercializing targeted therapeutics in patent-protected drug delivery technologies in the respiratory, oncology and critical care areas. A rapidly growing market, targeted therapeutics focus their action to specific cellular targets, reducing undesirable collateral damage while boosting efficacy. Accentia and its subsidiaries collectively provide vertically integrated capabilities that include pre-market research and outcomes analyses; marketing and selling branded pharmaceuticals by licensing or acquiring under-promoted products and late stage development compounds; and a proprietary bioreactor technology to perform contract production of custom-designed biologics, including vaccines.

"With interest in targeted therapeutics escalating, our investment in Accentia reflects our strategy of investing in companies that are developing leading edge therapies and technologies," said Fred Eshelman, chief executive officer of PPD. "It also complements our goal of seeking opportunities to increase potential for enhanced earnings."

In making the announcement, Frank O'Donnell, chairman and chief executive officer of Accentia, said, "The investment affirms our business model and strategy to position Accentia as a leader in targeted therapeutics, and we are very pleased to be aligned with a company of PPD's stature."

Accentia, Inc., a Hopkins Capital Group company, is a privately-held, vertically-integrated specialty biopharmaceutical company based in Tampa, Fla., that provides comprehensive biopharmaceutical services, including product commercialization, clinical manufacturing, contract sales and product distribution. For more information about Accentia, go to http://www.accentia.net/ .

As a leading global provider of discovery and development services and products for pharmaceutical, biotechnology and medical device companies, PPD applies innovative technologies, therapeutic expertise and a commitment to quality to help clients maximize the return on their R&D investments. With proven early discovery through post-market resources, the company also offers compound partnering opportunities. PPD has more than 5,700 professionals in 26 countries around the world. For more information on PPD, visit our Web site at http://www.ppdi.com/ .

Except for historical information, all of the statements, expectations and assumptions, including expectations and assumptions about the equity investment in Accentia, contained in this news release are forward-looking statements that involve a number of risks and uncertainties. Although PPD attempts to be accurate in making those forward-looking statements, it is possible that future circumstances might differ from the assumptions on which such statements are based. In addition, other important factors which could cause results to differ materially include the following: risks associated with investments, including impairments; economic conditions in the pharmaceutical, biotechnology and medical device industries; rapid technological advances that make the products and services of companies in which we invest less competitive; continued success in sales growth; the ability to attract and retain key personnel; and the other risk factors set forth from time to time in the SEC filings for PPD, copies of which are available free of charge upon request from the PPD investor relations department.

Contacts For Accentia For PPD Media: Media: Frank O'Donnell Nancy Zeleniak +813 864 2554 +919 462 4088 feomdjr@aol.comnancy.zeleniak@rtp.ppdi.com Analysts/Investors: Steve Smith +910 772 7585 stephen.smith@wilm.ppdi.com

PPD, Inc.

CONTACT: Media, Frank O'Donnell of Accentia, Inc., +1-813-864-2554, orfeomdjr@aol.com; or Nancy Zeleniak of PPD, +1-919-462-4088, ornancy.zeleniak@rtp.ppdi.com, or Analysts/Investors, Steve Smith of PPD,+1-910-772-7585, or stephen.smith@wilm.ppdi.com


Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES
 

//-->